Fosfomycin Holds Promise for Management of Complicated Urinary Tract Infection

Fosfomycin and ertapenem yielded comparable clinical outcomes in a retrospective study of patients with cUTI.

Extended-spectrum beta-lactamase (ESBL)–producing Entrobacteriacae are often resistant to quinolones and trimethoprim-sulfamethoxazole, leaving no FDA-approved oral options for patients with complicated urinary tract infections (cUTI). In a retrospective, multicenter study, investigators evaluated the clinical outcomes of off-label oral fosfomycin versus intravenous ertapenem in discharged patients receiving treatment for cUTI. The primary endpoint was resolution of clinical symptoms at day 30 without relapse.

Among 322 eligible cUTI episodes, 110 occurred in the fosfomycin group and 212 in the ertapenem group. E. coli and K. pneumoniae accounted for most cases in both groups. Demographic characteristics were comparable between groups, but m…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Fosfomycin Holds Promise for Management of Complicated Urinary Tract Infection

Topics

Reviewing Author